| PACKAGING TYPE: | 10x10 Blister (10 Strips In 1 Box) |
| COMPOSITION: | Gliclazide 60mg+pioglitazone 15mg+metformin Hydrocloride 500mg |
| FORMULATION: | Tablet |
| Description: | GLYZIMAC TOTAL 60 Tablet is a triple-combination antidiabetic medication containing: Gliclazide 60mg – a sulfonylurea that stimulates insulin secretion from pancreatic beta cells. Pioglitazone 15mg – a thiazolidinedione that improves insulin sensitivity in peripheral tissues. Metformin Hydrochloride 500mg – a biguanide that reduces hepatic glucose production and enhances insulin utilization. This advanced formulation is designed for the management of Type 2 Diabetes Mellitus, particularly in patients requiring intensive glycemic control. It provides comprehensive glucose regulation by targeting multiple mechanisms involved in blood sugar management. |
| Side Effects: | Common side effects: Nausea or gastrointestinal discomfort Weight gain (due to Pioglitazone) Headache Hypoglycemia Rare but serious side effects: Lactic acidosis (rare, due to Metformin) Fluid retention or edema Liver function abnormalities Severe hypoglycemia Allergic reactions (rash, swelling, difficulty breathing) |
| How to Use: | Take GLYZIMAC TOTAL 60 Tablet orally, usually once daily with meals or as prescribed. Swallow the tablet whole with water. Do not skip meals to avoid hypoglycemia. Maintain a healthy diet and regular exercise routine. Monitor blood glucose levels regularly. |
| Precaution: | Monitor for symptoms of hypoglycemia (sweating, dizziness, confusion). Use cautiously in patients with heart failure (due to Pioglitazone). Avoid excessive alcohol consumption (risk of lactic acidosis). Use with caution in liver and kidney impairment. Inform your doctor about all medications to avoid interactions. Not recommended during pregnancy or breastfeeding without medical advice. |
| Product Benefits: | Provides triple-action blood sugar control. Effectively reduces fasting and postprandial glucose levels. Enhances insulin secretion and insulin sensitivity. Helps reduce risk of diabetes-related complications. Higher strength for better glycemic contr |
Frequently Asked Questions
It is used for the management of Type 2 Diabetes Mellitus requiring triple-drug therapy.
Yes, it contains a higher dose of Gliclazide (60mg), making it more suitable for patients needing stronger glycemic control.
Yes, Pioglitazone in the combination may lead to weight gain or fluid retention.











